Altered TEG Parameters Identify Hypercoagulablilty and are of Diagnosis Value for Papillary Thyroid Carcinoma Patients

Abstract

Objective The goal of this study was to clarify the changes and clinical significance of thromboelastography (TEG) parameters in papillary thyroid carcinomas and nodular goiters.

Methods 62 nodular goiter (NG) patients and 53 papillary thyroid carcinoma (PTC) patients were included. Coagulation indicators, together with a series of TEG parameters were collected and analyzed, compared with results of 61 healthy controls (HC). Correlation analysis was conducted between routine coagulation indicators and TEG parameters. ROC curves were used to evaluate the potential diagnosis value of the TEG parameters that were altered in papillary thyroid carcinoma patients.

Results APTT and PT in papillary thyroid carcinoma group were statistically significant higher than that in control group (p<0.05). MPV was found to be higher in PTC than NG and healthy controls.

R, K and SP levels were significantly lower in PTC group than that in HC group; Angle, CI and TPI levels were significantly higher in PTC group than that in HC group. Areas under the ROC curve of CI, TPI, and angle were 0.725, 0.714, and 0.687 for distinguishing PTC from HC, 0.662, 0.668 and 0.591 for distinguishing PTC from NG.

Conclusion TEG parameters are altered and indicate hypercoagulablilty status of papillary thyroid carcinoma patients; CI, TPI, and angle could be potential diagnosis indicators for detecting papillary thyroid carcinoma.

Key words

thromboelastography - papillary thyroid carcinoma - nodular goiter - diagnosis

• References

• 1 Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 2009; 115: 3801-3807
• 2 Hay ID, Thompson GB, Grant CS. et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26: 879-885
• 3 Hegedus L, Bonnema SJ, Bennedbæk FN. Management of simple nodular goiter: Current status and future perspectives. Endocr Rev 2003; 24: 102-132
• 4 Rugeri L, Levrat A, David JS. et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007; 5: 289-295
• 5 Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. Transfus Med Rev 2012; 26: 1-3
• 6 Mendez-Angulo JL, Mudge MC, Couto CG. Thromboelastography in equine medicine: Technique and use in clinical research. Equine Vet Educ 2012; 24: 639-649
• 7 Schreiber MA. Coagulopathy in the trauma patient. Curr Opin Crit Care 2005; 11: 590-597
• 8 Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007; 5: 116-124
• 9 Chandler WL. The thromboelastography and the thromboelastograph technique. Semin Thromb Hemost 1995; 21: 001-006
• 10 Katori N, Tanaka KA, Szlam F. et al. The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg 2005; 100: 1781-1785
• 11 LI B, JIANG YX, ZHANG Y. Correlation between thromboelastography and conventional blood coagulation monitoring in liver transplantation. J Clin Anesthesiol 2011; 4: 340-342
• 12 Toukh M, Siemens DR, Black A. et al. Thromboelastography identifies hypercoagulablilty and predicts thromboembolic complications in patients with prostate cancer. Thromb Res 2014; 133: 88-95
• 13 Wehrum MJ, Hines JF, Hayes EB. et al. Comparative assessment of hypercoagulability in women with and without gynecologic malignancies using the thromboelastograph coagulation analyzer. Blood Coagul Fibrin 2010; 21: 140-143
• 14 Akay OM, Ustuner Z, Canturk Z. et al. Laboratory investigation of hypercoagulability in cancer patients using rotation thrombelastography. Med Oncol 2009; 26: 358-364
• 15 Franchini M. Hemostatic changes in thyroid diseases: Haemostasis and thrombosis. Hematology 2006; 11: 203-208
• 16 Lal G, Brennan TV, Hambleton J. et al. Coagulopathy, marantic endocarditis, and cerebrovascular accidents as paraneoplastic features in medullary thyroid cancer—case report and review of the literature. Thyroid 2003; 13: 601-605
• 17 Ordookhani A, Motazedi A, Burman KD. Thrombosis in Thyroid Cancer. Int J Endocrino Metab 2017; 16: e57897
• 18 Nielsen VG, Garol BD, Zelman EA. et al. Hemeoxygenase-1 mediated hypercoagulability in a patient with thyroid cancer. Blood Coagul Fibrin 2013; 24: 663-665
• 19 Bowbrick VA, Mikhailidis DP, Stansby G. The use of citrated whole blood in thromboelastography. Anesth Analg 2000; 90: 1086-1088
• 20 Traverso CI, Caprini JA, Arcelus JI. The normal thromboelastogram and its interpretation. Semin Thromb Hemost 1995; 21: 7-13
• 21 Donahue SM, Otto CM. Thromboelastography: a tool for measuring hypercoagulability, hypocoagulability, and fibrinolysis. J Vet Emerg Crit Care 2005; 15: 9-16
• 22 Ågren A, Wikman AT, Holmström M. et al. Thromboelastography (TEG^®) compared to conventional coagulation tests in surgical patients –A laboratory evaluation. Scand J Clin Lab Invest 2013; 73: 214-220
• 23 Goldenberg NA, Hathaway WE, Jacobson L. et al. A new global assay of coagulation and fibrinolysis. Thromb Res 2005; 116: 345-356
• 24 Elbers LP, Moran C, Gerdes VE. et al. The hypercoagulable state in hyperthyroidism is mediated via the thyroid hormone β receptor pathway. Eur J Endocrinol 2016; 174: 755-762
• 25 Kim N, Gu JY, Yoo HJ. et al. Contact system activation and high thrombin generation in hyperthyroidism. Eur J Endocrinol 2017; 176: 583-589
• 26 Cantürk Z, Çetinarslan B, Tarkun I. et al. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2003; 13: 971-977
• 27 Tiede DJ, Tefferi A, Kochhar R. et al. Paraneoplastic cholestasis and hypercoagulability associated with medullary thyroid carcinoma. Resolution with tumor debulking. Cancer 1994; 73: 702-705
• 28 Thorson CM, Van Haren RM, Ryan ML. et al. Pre-existing hypercoagulability in patients undergoing potentially curative cancer resection. Surgery 2014; 155: 134-144